Cargando…

The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy

BACKGROUND: N(6)-Methyladenosine (m6A) methylation is the most prevalent internal posttranscriptional modification on mammalian mRNA. The role of m6A mRNA methylation in the heart is not known. METHODS: To determine the role of m6A methylation in the heart, we isolated primary cardiomyocytes and per...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorn, Lisa E., Lasman, Lior, Chen, Jing, Xu, Xianyao, Hund, Thomas J., Medvedovic, Mario, Hanna, Jacob H., van Berlo, Jop H., Accornero, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340720/
https://www.ncbi.nlm.nih.gov/pubmed/30586742
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036146
_version_ 1783388828849930240
author Dorn, Lisa E.
Lasman, Lior
Chen, Jing
Xu, Xianyao
Hund, Thomas J.
Medvedovic, Mario
Hanna, Jacob H.
van Berlo, Jop H.
Accornero, Federica
author_facet Dorn, Lisa E.
Lasman, Lior
Chen, Jing
Xu, Xianyao
Hund, Thomas J.
Medvedovic, Mario
Hanna, Jacob H.
van Berlo, Jop H.
Accornero, Federica
author_sort Dorn, Lisa E.
collection PubMed
description BACKGROUND: N(6)-Methyladenosine (m6A) methylation is the most prevalent internal posttranscriptional modification on mammalian mRNA. The role of m6A mRNA methylation in the heart is not known. METHODS: To determine the role of m6A methylation in the heart, we isolated primary cardiomyocytes and performed m6A immunoprecipitation followed by RNA sequencing. We then generated genetic tools to modulate m6A levels in cardiomyocytes by manipulating the levels of the m6A RNA methylase methyltransferase-like 3 (METTL3) both in culture and in vivo. We generated cardiac-restricted gain- and loss-of-function mouse models to allow assessment of the METTL3-m6A pathway in cardiac homeostasis and function. RESULTS: We measured the level of m6A methylation on cardiomyocyte mRNA, and found a significant increase in response to hypertrophic stimulation, suggesting a potential role for m6A methylation in the development of cardiomyocyte hypertrophy. Analysis of m6A methylation showed significant enrichment in genes that regulate kinases and intracellular signaling pathways. Inhibition of METTL3 completely abrogated the ability of cardiomyocytes to undergo hypertrophy when stimulated to grow, whereas increased expression of the m6A RNA methylase METTL3 was sufficient to promote cardiomyocyte hypertrophy both in vitro and in vivo. Finally, cardiac-specific METTL3 knockout mice exhibit morphological and functional signs of heart failure with aging and stress, showing the necessity of RNA methylation for the maintenance of cardiac homeostasis. CONCLUSIONS: Our study identified METTL3-mediated methylation of mRNA on N(6)-adenosines as a dynamic modification that is enhanced in response to hypertrophic stimuli and is necessary for a normal hypertrophic response in cardiomyocytes. Enhanced m6A RNA methylation results in compensated cardiac hypertrophy, whereas diminished m6A drives eccentric cardiomyocyte remodeling and dysfunction, highlighting the critical importance of this novel stress-response mechanism in the heart for maintaining normal cardiac function.
format Online
Article
Text
id pubmed-6340720
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-63407202019-02-15 The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy Dorn, Lisa E. Lasman, Lior Chen, Jing Xu, Xianyao Hund, Thomas J. Medvedovic, Mario Hanna, Jacob H. van Berlo, Jop H. Accornero, Federica Circulation Original Research Articles BACKGROUND: N(6)-Methyladenosine (m6A) methylation is the most prevalent internal posttranscriptional modification on mammalian mRNA. The role of m6A mRNA methylation in the heart is not known. METHODS: To determine the role of m6A methylation in the heart, we isolated primary cardiomyocytes and performed m6A immunoprecipitation followed by RNA sequencing. We then generated genetic tools to modulate m6A levels in cardiomyocytes by manipulating the levels of the m6A RNA methylase methyltransferase-like 3 (METTL3) both in culture and in vivo. We generated cardiac-restricted gain- and loss-of-function mouse models to allow assessment of the METTL3-m6A pathway in cardiac homeostasis and function. RESULTS: We measured the level of m6A methylation on cardiomyocyte mRNA, and found a significant increase in response to hypertrophic stimulation, suggesting a potential role for m6A methylation in the development of cardiomyocyte hypertrophy. Analysis of m6A methylation showed significant enrichment in genes that regulate kinases and intracellular signaling pathways. Inhibition of METTL3 completely abrogated the ability of cardiomyocytes to undergo hypertrophy when stimulated to grow, whereas increased expression of the m6A RNA methylase METTL3 was sufficient to promote cardiomyocyte hypertrophy both in vitro and in vivo. Finally, cardiac-specific METTL3 knockout mice exhibit morphological and functional signs of heart failure with aging and stress, showing the necessity of RNA methylation for the maintenance of cardiac homeostasis. CONCLUSIONS: Our study identified METTL3-mediated methylation of mRNA on N(6)-adenosines as a dynamic modification that is enhanced in response to hypertrophic stimuli and is necessary for a normal hypertrophic response in cardiomyocytes. Enhanced m6A RNA methylation results in compensated cardiac hypertrophy, whereas diminished m6A drives eccentric cardiomyocyte remodeling and dysfunction, highlighting the critical importance of this novel stress-response mechanism in the heart for maintaining normal cardiac function. Lippincott Williams & Wilkins 2019-01-22 2018-11-28 /pmc/articles/PMC6340720/ /pubmed/30586742 http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036146 Text en © 2018 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research Articles
Dorn, Lisa E.
Lasman, Lior
Chen, Jing
Xu, Xianyao
Hund, Thomas J.
Medvedovic, Mario
Hanna, Jacob H.
van Berlo, Jop H.
Accornero, Federica
The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy
title The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy
title_full The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy
title_fullStr The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy
title_full_unstemmed The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy
title_short The N(6)-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy
title_sort n(6)-methyladenosine mrna methylase mettl3 controls cardiac homeostasis and hypertrophy
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340720/
https://www.ncbi.nlm.nih.gov/pubmed/30586742
http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036146
work_keys_str_mv AT dornlisae then6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT lasmanlior then6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT chenjing then6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT xuxianyao then6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT hundthomasj then6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT medvedovicmario then6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT hannajacobh then6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT vanberlojoph then6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT accornerofederica then6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT dornlisae n6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT lasmanlior n6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT chenjing n6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT xuxianyao n6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT hundthomasj n6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT medvedovicmario n6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT hannajacobh n6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT vanberlojoph n6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy
AT accornerofederica n6methyladenosinemrnamethylasemettl3controlscardiachomeostasisandhypertrophy